

Ref. No: FOI0101
Date: 30/06/2023
Subject: Multiple Myeloma

REQUEST

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- Belantamab Mafodotin [Blenrep]
- Bortezomib [Velcade] monotherapy or with dexamethasone
- Bortezomib, thalidomide and dexamethasone [VTD]
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
- Carfilzomib [Kyprolis] and dexamethasone
- Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
- Daratumumab [Darzalex] monotherapy
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
- Elranatamab
- Idecabtagene vicleucel [Abecma]
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
- Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
- Lenalidomide [Revlmid] monotherapy
- Lenalidomide [Revlmid] and dexamethasone
- Pomalidomide [Imnovid] and dexamethasone
- Selinexor and dexamethasone
- Talquetamab
- Teclistamab [Tecvayli]

Any other systemic anti-cancer therapy

RESPONSE

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

62 patients

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- Belantamab Mafodotin [Blenrep] – <5 patients
- Bortezomib [Velcade] monotherapy or with dexamethasone – 9 patients
- Bortezomib, thalidomide and dexamethasone [VTD] - Zero patients
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) – <5 patients
- Carfilzomib [Kyprolis] and dexamethasone – Zero patients
- Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone – Zero patients
- Daratumumab [Darzalex] monotherapy – 9 patients
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) – 9 patients
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) – <5 patients
- Elranatamab – Zero patients
- Idecabtagene vicleucel [Abecma] -Zero patients
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) – <5 patients
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) – 7 patients
- Lenalidomide [Revlimid] monotherapy – 7 patients
- Lenalidomide [Revlimid] and dexamethasone – 14 patients

- Pomalidomide [Imnovid] and dexamethasone – <5 patients
- Selinexor and dexamethasone – Zero patients
- Talquetamab – Zero patients
- Teclistamab [Tecvayli] – Zero patients

<5

Due to the low number of patients provided with these drugs which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.